【摘要】 ４５例经临床和脑ＣＴ扫描／ＭＲＩ确诊的急性期脑梗塞（ＣＩ）患者被随机分成东菱精纯克栓酶（巴曲酶，ＤＦ－５２１）治疗组（３０例）和血液稀释对照组（１５例）。二组患者均于治疗前和治疗后１周作神经功能缺损评分，结合治疗后患者的病残程度，评定临床疗效；同时作凝血功能、血粘度和血小板聚集率等实验室观测。结果表明，早期静脉滴注ＤＦ－５２１治疗ＣＩ安全、有效，总有效率为９３．３％，明显高于对照组（４６．７％，Ｐ＜０．０１）。ＤＦ－５２１能明显降低ＣＩ患者血粘度和血浆纤维蛋白原浓度，对ＡＤＰ诱导的血小板聚集反应有显著抑制作用，可作为ＣＩ早期抗栓溶栓疗法的一种新选择。更多还原

【Abstract】 patients with diagnosed cerebral infarction were randomized to re-ceive Tobishi batro-xobin(DF-521)in 30 cases and placebo in 15 cases. In order to eval-uate clinical efficacy of DF-521,the neurological deficit scores of all patients were calcu-lated before and one week after treatment.Results showed that the ovefall effective rate of the active group is remarkably higher than that of the control group(93.3%VS 46.7%,P<0.01)and the blood viscosity,plasma fibrinogen concentration and platelet aggregation rate were significantly reduced in active group.更多还原